KPV vs BPC-157
Two research peptides studied mostly in cells and animals: an anti-inflammatory tripeptide and a pro-angiogenic pentadecapeptide.
Research use only. A summary of published literature for educational reference — not medical advice and not a guide to human use.
The short version
KPV (Lys-Pro-Val) reduced intestinal inflammation in cell and mouse colitis experiments. BPC-157 promoted blood-vessel growth in cell and rat experiments, and its only human report is a two-person safety pilot. Neither has a published human efficacy trial.
At a glance
Structure
Tripeptide (Lys-Pro-Val)
15-amino-acid peptide
Approval status
No approved indication
No approved indication
Proposed mechanism
PepT1 uptake; blocks NF-κB/MAPK inflammatory signalling
VEGFR2 and Akt-eNOS signalling (angiogenesis)
Human data
None identified
Uncontrolled two-person safety pilot
Research vial sizes
10 mg
5 / 10 mg
The details · tap a section to open it
01
How they work
KPV is taken up by gut cells through the PepT1 transporter and, in experiments, blocked NF-κB and MAPK inflammatory signalling, lowering inflammatory cytokines.
01
How they work
KPV is taken up by gut cells through the PepT1 transporter and, in experiments, blocked NF-κB and MAPK inflammatory signalling, lowering inflammatory cytokines.
KPV is taken up by gut cells through the PepT1 transporter and, in experiments, blocked NF-κB and MAPK inflammatory signalling, lowering inflammatory cytokines.
BPC-157's proposed effects centre on new blood-vessel growth: in cell and animal work it was linked to VEGFR2 activation and the Akt-eNOS pathway. Neither mechanism has been validated in people.
02
What studies measured
Dalmasso and colleagues used intestinal cells and two mouse colitis models (DSS and TNBS); KPV reduced inflammatory signalling and tissue inflammation. The abstract does not give animal numbers or effect sizes.
02
What studies measured
Dalmasso and colleagues used intestinal cells and two mouse colitis models (DSS and TNBS); KPV reduced inflammatory signalling and tissue inflammation. The abstract does not give animal numbers or effect sizes.
Dalmasso and colleagues used intestinal cells and two mouse colitis models (DSS and TNBS); KPV reduced inflammatory signalling and tissue inflammation. The abstract does not give animal numbers or effect sizes.
Hsieh and colleagues found BPC-157 increased vessel formation in cell assays and improved blood-flow recovery in a rat limb-ischemia model.
A 2025 pilot gave BPC-157 to two adults who had used it before and found no measurable changes in cardiac, liver, kidney, thyroid or glucose markers.
03
Evidence limits
Animal and cell findings do not establish benefit in humans. A two-person uncontrolled pilot cannot detect uncommon harms or long-term effects. Product identity and purity also vary between suppliers.
03
Evidence limits
Animal and cell findings do not establish benefit in humans. A two-person uncontrolled pilot cannot detect uncommon harms or long-term effects. Product identity and purity also vary between suppliers.
Animal and cell findings do not establish benefit in humans. A two-person uncontrolled pilot cannot detect uncommon harms or long-term effects. Product identity and purity also vary between suppliers.
Citations
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
3 papers
Citations
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
- [1]Cell-culture and mouse colitis experiments2008
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Dalmasso G, et al. Gastroenterology, 2008.
Read paper ↗ - [2]Preclinical cell and animal experiments2017
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Hsieh MJ, et al. J Mol Med, 2017.
Read paper ↗ - [3]Uncontrolled two-participant safety pilot2025
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Lee E, et al. Altern Ther Health Med, 2025.
Read paper ↗
Research use only. A summary of published literature for educational reference — not medical advice and not a guide to human use.